Price T Rowe Associates Inc Bei Gene, Ltd. Transaction History

Price T Rowe Associates Inc

  • $935 Billion
  • Q3 2025

A detailed history of Price T Rowe Associates Inc transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,630,571 shares of BGNE stock, worth $370 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
1,630,571
Previous 1,020,127 59.84%
Holding current value
$370 Million
Previous $247 Million 124.97%
% of portfolio
0.06%
Previous 0.03%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
BUY
N/A
610,444 Added 59.84%
1,630,571 $556 Million
Q2 2025

Aug 14, 2025
SELL
N/A
-1,693,291 Reduced 62.4%
1,020,127 $247 Million
Q1 2025

May 14, 2025
SELL
$175.1 - $226.71 $39.2 Million - $50.7 Million
-223,752 Reduced 7.62%
2,713,418 $739 Million
Q4 2024

Feb 14, 2025
BUY
$174.72 - $246.04 $41.4 Million - $58.3 Million
237,082 Added 8.78%
2,937,170 $543 Million
Q3 2024

Nov 14, 2024
BUY
$143.93 - $224.51 $61.5 Million - $95.9 Million
427,266 Added 18.8%
2,700,088 $606 Million
Q2 2024

Aug 14, 2024
BUY
$129.52 - $174.32 $32 Million - $43 Million
246,728 Added 12.18%
2,272,822 $324 Million
Q1 2024

May 15, 2024
BUY
$141.8 - $181.47 $16.7 Million - $21.4 Million
117,905 Added 6.18%
2,026,094 $317 Million
Q4 2023

Feb 14, 2024
BUY
$158.67 - $201.58 $25.2 Million - $32 Million
158,624 Added 9.07%
1,908,189 $344 Million
Q3 2023

Nov 14, 2023
BUY
$179.87 - $225.13 $47.6 Million - $59.6 Million
264,691 Added 17.83%
1,749,565 $315 Million
Q2 2023

Aug 14, 2023
BUY
$178.3 - $266.78 $126 Million - $189 Million
709,017 Added 91.39%
1,484,874 $265 Million
Q1 2023

May 15, 2023
BUY
$215.53 - $274.5 $67.8 Million - $86.4 Million
314,764 Added 68.26%
775,857 $167 Million
Q4 2022

Feb 14, 2023
BUY
$125.51 - $229.3 $1.72 Million - $3.14 Million
13,676 Added 3.06%
461,093 $101 Million
Q3 2022

Nov 14, 2022
SELL
$131.8 - $202.24 $1.94 Million - $2.98 Million
-14,727 Reduced 3.19%
447,417 $60.3 Million
Q2 2022

Aug 15, 2022
SELL
$121.11 - $216.05 $7.79 Million - $13.9 Million
-64,352 Reduced 12.22%
462,144 $74.8 Million
Q1 2022

May 16, 2022
SELL
$146.52 - $269.56 $4.58 Million - $8.43 Million
-31,264 Reduced 5.61%
526,496 $99.3 Million
Q4 2021

Feb 14, 2022
SELL
$248.56 - $389.34 $3.25 Million - $5.1 Million
-13,093 Reduced 2.29%
557,760 $151 Million
Q3 2021

Nov 15, 2021
SELL
$249.6 - $403.14 $2.81 Million - $4.53 Million
-11,240 Reduced 1.93%
570,853 $207 Million
Q2 2021

Aug 16, 2021
SELL
$292.75 - $367.01 $43.3 Million - $54.3 Million
-147,837 Reduced 20.25%
582,093 $200 Million
Q1 2021

May 17, 2021
SELL
$260.64 - $382.12 $28 Million - $41.1 Million
-107,448 Reduced 12.83%
729,930 $254 Million
Q4 2020

Feb 16, 2021
BUY
$221.31 - $316.61 $185 Million - $265 Million
837,378 New
837,378 $216 Million

Others Institutions Holding BGNE

# of Institutions
298
Shares Held
30.4M
Call Options Held
147K
Put Options Held
195K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23.5B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email